Relationship between IL-10 and tumor markers in breast cancer patients

Breast

Volumn 15, Issue 4, 2006, Pages 482-489

  Llanes Fernández, Leticia ^a   Álvarez Goyanes, Rosa Irene ^a   Arango Prado, Maria del Carmen ^a   Alcocer González, Juan Manuel ^b   Mojarrieta, Julia Cruz ^a   Pérez, Xiomara Escobar ^a   López, Maiby Orozco ^a   Odio, Sonia Franco ^a   Camacho Rodríguez, Rolando ^a   Guerra Yi, Marta Elena ^a   Madrid Marina, Vicente ^c   Tamez Guerra, Reyes ^b   Rodríguez Padilla, Cristina ^b  

^a INSTITUTO NACIONAL DE ONCOLOGÍA Y RADIOBIOLOGÍA   (Cuba)

^b UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

^c INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

Author keywords

BcL 2 family; Breast cancer; ER; Her 2; IL 10; p53

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; INTERLEUKIN 10; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; TUMOR MARKER;

ADULT; AGED; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER INHIBITION; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOHISTOCHEMISTRY; INHIBITION KINETICS; MICROENVIRONMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR CELL; TUMOR LOCALIZATION;

EID: 33746721569     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2005.09.012     Document Type: Article

References (34)

1. Esteva F.J., and Hortobagyi G.N. Prognostic molecular markers in early breast cancer. Breast Cancer Res 6 (2004) 109-118
2. Yamashita H., Nishio M., Toyama T., et al. Coexistence of Her2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer. Breast Cancer Res 6 (2004) R24-R30
3. Wong P.Y., Staren E.D., Tereshkova N., and Braun D.P. Functional analysis of tumor-infiltrating leukocytes in breast cancer patients. J Surg Res 76 (1998) 95-103
4. Venetsanakos E., Beckman I., Bradley J., and Skinner J.M. High incidence of interleukin 10 mRNA but not interleukin 2 mRNA detected in human breast tumours. Br J Cancer 75 (1997) 1826-1830
5. Huang M., Wang J., Lee P., et al. Human non-small cell lung cancer cells express a type 2 cytokine pattern. Cancer Res 55 (1995) 3847-3853
6. Green A.R., Green V.L., White M.C., and Speirs V. Expression of cytokine messenger RNA in normal and neoplastic human breast tissue: identification of interleukin-8 as a potential regulatory factor in breast tumours. Int J Cancer 72 (1997) 937-941
7. Marrogi A.J., Munshi A., Merogi A.J., et al. Study of tumor infiltrating lymphocytes and transforming growth factor-beta as prognostic factor in breast carcinoma. Int J Cancer 74 (1997) 492-501
8. Fiorentino D.F., Zlotnick A., Vieira P., et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 146 (1991) 3444-3451
9. O'Garra A.K.W., de Waal Malefyt R., Vieira P., and Mosmann T.R. Interleukin-10. Annu Rev Immunol 11 (1993) 165-190
10. Cohen S.B., Crawley J.B., Kahan M.C., Feldmann M., and Foxwell B.M. Interleukin-10 rescues T cells from apoptotic cell death: association with an upregulation of Bcl-2. Immunology 92 (1997) 1-5
11. Taga K., Cherney B., and Tosato G. IL-10 inhibits apoptotic cell death in human T cells starved of IL-2. Int Immunol 5 (1993) 1599-1608
12. Alas S., and Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (stat3) activity in b-non-hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of bcl-2 and sensitization to cytotoxic drugs. Cancer Res 61 (2001) 5137-5144
13. Wang X.Z., Zhang S.J., Chen Y.X., Chen Z.X., Huang Y.H., and Zhang L.J. Effects of platelet-derived growth factor and interleukin-10 on Fas/Fas-ligand and Bcl-2/Bax mRNA expression in rat hepatic stellate cells in vitro. World J Gastroenterol 10 (2004) 2706-2710
14. Okuda Y., Okuda M., and Bernard C.C. Regulatory role of p53 in experimental autoimmune encephalomyelitis. J Neuroimmunol 135 (2003) 29-37
15. Ohkuso-Tsukada K., Tsukada T., and Isobe K.I. Accelerated development and aging of the immune system in p53-deficient mice. J Immunol 163 (1999) 1966-1972
16. Coppola D., Catalano E.S.V., and Nicosia S.V. Pathology update significance of p53 and Bcl-2 protein expression in human breast ductal carcinoma. Cancer Control 6 (1999) 181-187
17. Megha T., Ferrari F., Benvenuto A., et al. p53 mutation in breast cancer. Correlation with cell kinetics and cell of origin. J Clin Pathol 55 (2002) 461-466
18. Ellis M. Overcoming endocrine therapy resistance by signal transduction inhibition. Oncologist 9 (2004) 20-26
19. Sjostrom J., Blomqvist C., von Boguslawski K., et al. The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer. Clin Cancer Res 8 (2002) 811-816
20. Osin PP, Lakhani SR. The pathology of familial breast cancer: immunohistochemistry and molecular analysis [review]. http://breast-cancer-research.com/vol1no1/27oct99/review/3
21. Yang Q.F., Sakurai T., Yoshimura G., et al. Expression of Bcl-2 but not Bax or p53 correlates with in vitro resistance to a series of anticancer drugs in breast carcinoma. Breast Cancer Res Treat 61 (2000) 211-216
22. Martinez-Arribas F., Nunez-Villar M.J., Lucas A.R., Sanchez J., Tejerina A., and Schneider J. Immunofluorometric study of Bcl-2 and Bax expression in clinical fresh tumor samples from breast cancer patients. Anticancer Res 23 (2003) 565-568
23. Tsutsui S., Ohno S., Murakami S., Kataoka A., Kinoshita J., and Hachitanda Y. Prognostic significance of the coexpression of p53 protein and c-erbB2 in breast cancer. Am J Surg 185 (2003) 165-167
24. Navarro-Gómez J., Arafat W., and Xiang J. Gene therapy for carcinoma of the breast pro-apoptotic gene therapy. Breast Cancer Res 2 (1999) 32-44
25. Halak B.K., Maguirre Jr. H.C., and Lattime E.C. Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site. Cancer Res 59 (1999) 911-917
26. Beissert S., Hosoi J., Grabbe S., Asahina A., and Granstein R.D. IL-10 inhibits tumor antigen presentation by epidermal antigen-presenting cells. J Immunol 154 (1995) 1280-1286
27. Toomey D., Harmey J., Condron C., Kay E., and Bouchier-Hayes D. Phenotyping of immune cell infiltrates in breast and colorectal tumours. Immunol Invest 28 (1999) 29-41
28. + melanoma. Int Immunol 5 (1993) 1501-1508
29. Reed J.C., Miyashita T., Takayama S., et al. Bcl-2 family proteins: regulators of cell death involved in pathogenesis of cancer and resistance to therapy. J Chem Biochem 60 (1996) 23-32
30. Hashimoto S., Komuro I., Yamada M., and Akagawa K.S. IL-10 inhibits granulocyte macrophage colony-stimulating factor dependent human monocyte survival at the early stage of the culture and inhibits the generation of macrophages. J Immunol 167 (2001) 3619-3625
31. Alas S., Emmanouilides C., and Bonavida B. Inhibition of interleukin 10 by rituximab results in down-regulation of Bcl-2 and sensitization of B-cell Non-Hodgkin's Lymphoma to apoptosis. Clin Cancer Res 7 (2001) 709-723
32. Amirghofran Z., Monabati A., Khezri A., and Malek-Hosseini A. Apoptosis in transitional cell carcinoma of bladder and its relation to proliferation and expression of p53 and Bcl-2. Pathol Oncol Res 10 (2004) 154-158
33. Fox J.G., Sheppard B.J., Dangler C.A., Whary M.T., Ihrig M., and Wang T.C. Germ-line p53-targeted disruption inhibits helicobacter-induced premalignant lesions and invasive gastric carcinoma through down-regulation of Th1 proinflammatory responses. Cancer Res 62 (2002) 696-702
34. Parajuli P., Pisarev V., Sublet J., Steffel A., Varney M., and Singh R. Immunization with wild-type p53 gene sequences coadministered with Flt3 ligand induces an antigen-specific type 1 T-cell response. Cancer Res 61 (2001) 8227-8234